Accessibility Menu
Opko Health logo

Opko Health(NASDAQ) OPK

Market Cap$1.11BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1995)-67%
5 Year-61%
1 Year+7%
1 Month+22%
Premium Feature
Moneyball Superscore
44/100
$1.50
+0.67%
+0.01Today
Opko Health last closing stock price
MetricPriceDate
Last closeUSD 1.492026-08-25
Opko Health stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+9.56%USD 1.362026-08-18
1 month+22.13%USD 1.222026-07-24
3 month+14.62%USD 1.302026-05-27
Year to date+18.25%USD 1.262025-12-31
1 year+7.19%USD 1.392025-08-25
3 year-13.87%USD 1.732023-08-25
5 year-60.58%USD 3.782021-08-26
Since inception-66.89%USD 4.501995-11-02

Opko Health Financials at a Glance

Market Cap

$1.11BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$587.90M

Net Income (TTM)

-$72.89M

EPS (TTM)

-$0.10

P/E Ratio

-15.44

Dividend

$0.00

Beta (Volatility)

1.26 (Average)

Price

$1.50

Volume

446,272.449

Open

$1.50

Previous Close

$1.49

Daily Range

$1.48 - $1.52

52-Week Range

$0.98 - $1.73

Estimated Earnings Date

Nov 4, 2026

OPK News

Healthcare professional inspecting charts

Why Opko Health Stock Surged by 33% on Tuesday

Eric VolkmanJul 28, 2026
Foolcom-Featured.png

Opko Health (OPK) Q2 Revenue Falls 14%

Motley Fool Markets TeamAug 1, 2025
Young patient with doctor at appointment

Why Shares of Opko Health Jumped on Thursday

James HalleyJun 29, 2023
rising stock charts

Why OPKO Health Shares Jumped on Wednesday

James BrumleyMar 8, 2023
Person using a diagnostic health test

Why Opko Health Stock Was a Surprise Winner This Week

Eric VolkmanAug 11, 2022
Board - silhouettes at a conference table

Why Opko Health Stock Is Jumping Today

Keith SpeightsMay 10, 2022
Woman using a diagnostic health test

Why Opko Health Stock Dipped on Friday

Eric VolkmanFeb 25, 2022
FDA not approved

Why Opko Health Stock Is Crashing This Week

Keith SpeightsJan 27, 2022
Page 1

OPK: Motley Fool Moneyball Superscore

44

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Opko Health

OPKO Health, Inc. helps doctors find and treat illnesses. It creates medicines for kidney disease and growth issues. The company also runs labs to test for cancer.

Diagnostic Tools and Therapeutics

  • Laboratory Services: Clinical and women's health testing provided through BioReference Health; accounted for $74.5 million in service revenue for the three-month period ended June 30, 2026.
  • Hormone Therapies: NGENLA once-weekly injection for growth disturbances; marketed through a partnership with Pfizer.
  • Kidney Disease Treatments: Rayaldee oral capsules for chronic kidney disease; generated $8.1 million in product revenue during the second quarter of 2026.
  • Prostate Screening: 4Kscore diagnostic test used for prostate cancer evaluation; offered through a national urology franchise.

Strategic Sales and Global Partnerships

  • Completed the sale of the oncology diagnostics business to Labcorp for $192.5 million in September 2025.
  • Secured an $18.4 million earnout payment from Labcorp during the second quarter of 2026.
  • Expanded a licensing agreement with Nicoya Macau Limited in April 2026 for Rayaldee in Greater China.
  • Received a 15% equity stake in Nicoya Therapeutics Cayman as part of revised commercial terms.

Global Reach and Innovation

OPKO operates established pharmaceutical platforms in Spain, Ireland, Chile, and Mexico. These regional bases facilitate international manufacturing and export products to more than 60 countries.

A Look at the Numbers

  • Total revenues were $163.6 million for the three-month period ended June 30, 2026, up 4% year over year.
  • Revenue from services was $146.7 million for the six-month period ended June 30, 2026, down 28% year over year.
  • Operating loss was $7.0 million for the three-month period ended June 30, 2026, down 88% year over year.
  • Cash, cash equivalents, and restricted cash totaled $314.4 million on June 30, 2026.
  • The company had a market capitalization of $1.1 billion as of the second quarter of 2026.

The Path Forward

OPKO has transitioned from a broad diagnostic provider to a focused healthcare company emphasizing specialty testing and international pharmaceutical platforms. Strategic divestitures and global partnerships have helped streamline operations toward core therapeutic and diagnostic areas.

AI Generated • Jul 28, 2026

Industry

Healthcare Providers and Services

Sector

Health Care

Employees

2,275

CEO

Phillip Frost, MD

Website

www.opko.com

Headquarters

Miami, FL 33137, US

OPK Financials

Key Financial Metrics (TTM)

Gross Margin

30.98%

Operating Margin

-25.49%

Net Income Margin

-12.40%

Return on Equity

-5.88%

Return on Capital

-12.87%

Return on Assets

-3.98%

Earnings Yield

-6.48%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.11BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

746.33M

Volume

446.27K

Avg. Volume

3.51M

Financials (TTM)

Gross Profit

$182.14M

Operating Income

-$149.83M

EBITDA

$46.47M

Operating Cash Flow

-$123.38M

Capital Expenditure

-$10.64M

Free Cash Flow

-$134.02M

Cash & ST Invst.

$300.76M

Total Debt

$392.26M

Opko Health Performance Analysis

Opko Health annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 1,004,196,000-43.4%
20232023-12-31USD 863,495,000-14.0%
20242024-12-31USD 713,142,000-17.4%
20252025-12-31USD 606,879,000-14.9%
Opko Health sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-3.3%
Q42025-12-31-2.1%
Q12026-03-31-16.3%
Q22026-06-3031.7%
Opko Health annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.46882.2%
20232023-12-31USD -0.25-45.0%
20242024-12-31USD -0.08-69.5%
20252025-12-31USD -0.30291.7%
Opko Health sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30114.6%
Q42025-12-31-247.3%
Q12026-03-31-77.2%
Q22026-06-3086.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$163.58M

+4.3%

Gross Profit

$80.02M

+167.1%

Gross Margin

48.92%

N/A

Market Cap

$1.11BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$488.80K

N/A

Employees

2,275

N/A

Net Income

-$8.42M

+94.3%

EBITDA

$12.00M

+117.3%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$300.76M

+10.7%

Total Debt

$392.26M

-0.9%

Accounts Receivable

$114.91M

-14.6%

Inventory

$61.85M

-6.8%

Long Term Debt

$370.69M

+0.1%

Short Term Debt

$21.57M

-15.5%

Return on Assets

-3.98%

N/A

Return on Invested Capital

-8.92%

N/A

Free Cash Flow

-$46.50M

+46.4%

Operating Cash Flow

-$43.50M

+47.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SANASana Biotechnology, Inc.
$4.11+0.20%
PCRXPacira BioSciences, Inc.
$26.00+1.84%
TNDMTandem Diabetes Care, Inc.
$21.30-1.30%
OCSOculis Holding AG
$12.99+0.23%

Trending Stocks

Symbol / CompanyPricePrice Chg
CRECre8 Enterprise
$7.70+2.00%
DAICCid HoldCo
$5.20+0.34%
NVDANvidia
$210.53-0.01%
SNAPSnap
$5.48-0.08%

Questions About OPK

What is the current price of Opko Health?

Opko Health is trading at $1.48 per share.

What is the 52-week range for Opko Health?

Over the past 52 weeks, Opko Health has traded between $0.98 and $1.73.

How much debt does Opko Health have?

As of the most recent reporting period, Opko Health reported total debt of $398.08M.

How much cash does Opko Health have on hand?

Opko Health reported $300.76M in cash and cash equivalents in its most recent financial results.

What is Opko Health’s dividend yield?

Opko Health does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services